New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
05:37 EDTCTICCTI announce UK National Cancer Research Institute Phase 2 trial for Pacritinib
Cell Therapeutics announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia, or AML, with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis. Pacritinib is an oral JAK2/FLT3 inhibitor that has demonstrated encouraging activity in preclinical models of AML with mutated FLT3 gene, including additional FLT3 mutations that confer resistance to other targeted FLT3 agents. The trial is being conducted by the AML Working Group of the National Cancer Research Institute Haematological Oncology Study Group in AML and high risk Myelodysplastic Syndrome under the sponsorship of Cardiff University and supported by Cancer Research UK. This Phase 2 trial is part of a larger ongoing study in AML, referred to as the AML17 trial, which includes multiple arms evaluating first line regimens for AML. Patients with the FLT3 mutation, who are enrolled in this study and relapse following standard therapy, will be offered therapy with pacritinib. Approximately 80 patients at sites in England and Wales will be enrolled and, if an encouraging response rate is observed, a pacritinib arm may be adopted in the first line therapy study.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
16:18 EDTCTICCTI BioPharma raises FY14 operating loss view to $66M-$71M from $45M-$50M
As a result of the stock issuance in the transaction described above with Chroma resulting in an expense recognition of approximately $21M, CTI has revised its financial guidance such that non-GAAP operating loss for 2014 is now expected to range from approximately $66M-$71M rather than $45M-$50M as previously expected, which excludes non-cash share-based compensation expense.
16:16 EDTCTICCTI BioPharma reports Q3 EPS 3c, consensus (3c)
Reports Q3 revenue $39.53M, consensus $24.3M.
October 27, 2014
05:14 EDTCTICCTI BioPharma acquires exclusive worldwide license to tosedostat
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use